Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2023
Cadrenal Therapeutics granted FDA fast track designation for tecarfarin for prevention of systemic thromboembolism of cardiac origin in patients with end stage renal disease and atrial fibrillation
23 January 2023 - Cadrenal Therapeutics announced today that the US FDA has granted a fast track designation to tecarfarin ...
Posted by Michael Wonder on 22 Jan 2023
DualityBio announces DB-1303 granted fast track designation by the US FDA for the treatment of advanced, recurrent or metastatic endometrial carcinoma with HER2 overexpression
20 January 2023 - Duality Biologics announced that the US FDA has granted fast track designation to DB-1303 for the treatment ...
Posted by Michael Wonder on 21 Jan 2023
MedPacto receives US FDA fast track designation for vactosertib for the treatment of metastatic osteosarcoma
17 January 2023 - MedPacto announced that the US FDA has granted fast track designation to vactosertib as a monotherapy ...
Posted by Michael Wonder on 19 Jan 2023
Evaxion receives FDA fast track designation for personalised cancer immunotherapy
19 January 2023 - Evaxion Biotech today announced that the US FDA has granted fast track designation for the Company’s ...
Posted by Michael Wonder on 18 Jan 2023
Avidity Biosciences granted FDA fast track designation for AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy
18 January 2023 - Avidity Biosciences today announced that the US FDA has granted fast track designation to AOC 1020 for ...
Posted by Michael Wonder on 11 Jan 2023
Treadwell Therapeutics announces fast track designation granted by the FDA to CFI-402257 for the treatment of ER+/HER2- breast cancer
10 January 2023 - Treadwell Therapeutics announced today that the US FDA has granted fast track designation to CFI-402257, a best ...
Posted by Michael Wonder on 11 Jan 2023
UNION therapeutics receives FDA fast track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa
10 January 2023 - Orismilast is a high potency PDE4 inhibitor with broad anti-inflammatory properties also in development for oral ...
Posted by Michael Wonder on 06 Jan 2023
Bicycle Therapeutics announces FDA fast track designation granted to BT8009 for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer
4 January 2023 - Bicycle Therapeutics today announced that the US FDA has granted fast track designation to Bicycle’s BT8009 ...
Posted by Michael Wonder on 06 Jan 2023
Azafaros receives fast track designation for lead asset AZ-3102
5 January 2023 - Azafaros today announced that the FDA has granted fast track designation for the investigation of AZ-3102 for ...
Posted by Michael Wonder on 05 Jan 2023
Sedana Medical receives FDA fast track designation in the US
4 January 2023 - Sedana Medical today announces that the US FDA has granted fast track designation for the evaluation of ...
Posted by Michael Wonder on 21 Dec 2022
FDA grants fast track to Edesa Biotech's ARDS drug candidate
20 December 2022 - Edesa Biotech has received fast track designation from the US FDA for its monoclonal antibody candidate, EB05. ...
Posted by Michael Wonder on 13 Dec 2022
PharmaJet Partner Immunomic Therapeutics receives FDA fast track designation for pDNA vaccine for skin cancer
13 December 2022 - Vaccine exclusively delivered with the PharmaJet Stratis needle-free injection system. ...
Posted by Michael Wonder on 10 Dec 2022
Pfizer and BioNTech receive US FDA fast track designation for single dose mRNA based vaccine candidate against COVID-19 and influenza
9 December 2022 - Pfizer and BioNTech today announced the companies have received fast track designation from the US FDA ...
Posted by Michael Wonder on 07 Dec 2022
Moleculin granted FDA fast track designation of WP1122 for the treatment of glioblastoma multiforme
7 December 2022 - Moleculin Biotech today announced that the US FDA has granted fast track designation of WP1122 for the ...
Posted by Michael Wonder on 06 Dec 2022
SQZ Biotechnologies receives FDA fast track designation for its eAPC therapeutic candidate for treatment of HPV16 positive tumours
6 December 2022 - Stable disease observed in two out of four evaluable patients in eAPC Phase 1/2 trial including a ...